Fotivda for Advanced renal cell carcinoma
Quick answer: Fotivda is used for Advanced renal cell carcinoma as part of a tyrosine kinase inhibitor (vegfr) treatment regimen. Tivozanib selectively inhibits VEGFR-1, -2, and -3 tyrosine kinases to block tumor angiogenesis The specific dosing for Advanced renal cell carcinoma is determined by your prescriber based on individual factors.
Why is Fotivda used for Advanced renal cell carcinoma?
Fotivda belongs to the Tyrosine kinase inhibitor (VEGFR) class. Tivozanib selectively inhibits VEGFR-1, -2, and -3 tyrosine kinases to block tumor angiogenesis This action makes it useful for treating or managing Advanced renal cell carcinoma in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Fotivda is the right choice for a specific patient depends on the type and severity of Advanced renal cell carcinoma, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Advanced renal cell carcinoma
Common adult dosing range: 1.34 mg orally once daily for 21 days, then 7 days off (28-day cycle). The actual dose for Advanced renal cell carcinoma depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Fotivda medicine page.
What to expect
Fotivda treatment for Advanced renal cell carcinoma typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Advanced renal cell carcinoma
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Fotivda is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Tyrosine kinase inhibitor (VEGFR) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Fotivda
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Fotivda full prescribing information · All Tyrosine kinase inhibitor (VEGFR) alternatives
Frequently asked questions
How effective is Fotivda for Advanced renal cell carcinoma?
Effectiveness varies by individual response, dose, and severity. Fotivda is one of several treatment options for Advanced renal cell carcinoma, supported by clinical evidence within the tyrosine kinase inhibitor (vegfr) class. Discuss expected response with your prescriber.
How long do I need to take Fotivda for Advanced renal cell carcinoma?
Treatment duration depends on the nature of Advanced renal cell carcinoma — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Fotivda when used for Advanced renal cell carcinoma?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Fotivda for Advanced renal cell carcinoma?
Yes. Multiple medicines and non-drug options exist for Advanced renal cell carcinoma. Alternatives within the tyrosine kinase inhibitor (vegfr) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.